DOP2014000251A - Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo - Google Patents

Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo

Info

Publication number
DOP2014000251A
DOP2014000251A DO2014000251A DO2014000251A DOP2014000251A DO P2014000251 A DOP2014000251 A DO P2014000251A DO 2014000251 A DO2014000251 A DO 2014000251A DO 2014000251 A DO2014000251 A DO 2014000251A DO P2014000251 A DOP2014000251 A DO P2014000251A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical dosage
dosage form
cilexetilo
candesartán
manufacturing procedure
Prior art date
Application number
DO2014000251A
Other languages
English (en)
Inventor
Peter Kleinebudde
Arian Funke
GüNTER MEYER
Martina Smikalla
Andreas Meeners
Markus Wirges
Daniela Brock
Sarah Just
Klaus Knop
Axel Jochen Zeitler
Rolf-Anton Boeggering
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2014000251A publication Critical patent/DOP2014000251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a procedimientos de fabricación para la preparación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo y, opcionalmente, al menos un diurético, caracterizada porque la nifedipina se libera en el organismo de una manera controlada (modificada) y el candesartán cilexetilo se libera rápidamente (liberación inmediata [LI]) y, opcionalmente, el diurético se libera rápidamente (liberación inmediata [LI]), y a las formas de dosificación farmacéuticas que se pueden obtener mediante dichos procedimientos.
DO2014000251A 2012-05-07 2014-11-06 Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo DOP2014000251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167035 2012-05-07
EP13151946 2013-01-18

Publications (1)

Publication Number Publication Date
DOP2014000251A true DOP2014000251A (es) 2014-12-31

Family

ID=48289160

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000251A DOP2014000251A (es) 2012-05-07 2014-11-06 Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo

Country Status (27)

Country Link
US (1) US9539176B2 (es)
EP (1) EP2846777B1 (es)
JP (1) JP6231553B2 (es)
KR (1) KR20150007297A (es)
CN (1) CN104507459A (es)
AR (1) AR090940A1 (es)
AU (1) AU2013258273A1 (es)
BR (1) BR112014027618A2 (es)
CA (1) CA2872542A1 (es)
CL (1) CL2014002988A1 (es)
CO (1) CO7190241A2 (es)
CR (1) CR20140511A (es)
DO (1) DOP2014000251A (es)
EA (1) EA201492026A1 (es)
EC (1) ECSP14025965A (es)
ES (1) ES2612532T3 (es)
GT (1) GT201400245A (es)
HK (1) HK1204292A1 (es)
IL (1) IL235040A0 (es)
IN (1) IN2014DN09045A (es)
MX (1) MX2014013320A (es)
PE (1) PE20142284A1 (es)
PH (1) PH12014502469A1 (es)
SG (1) SG11201406363VA (es)
TW (1) TW201410266A (es)
UY (1) UY34786A (es)
WO (1) WO2013167453A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9244004B2 (en) * 2013-08-08 2016-01-26 Stichting Sron—Netherlands Institute For Space Research Method and system for inspection of composite assemblies using terahertz radiation
US10071482B2 (en) 2015-08-19 2018-09-11 Ford Global Technologies, Llc Robotic vehicle painting instrument including a terahertz radiation device
US10365229B2 (en) * 2015-12-31 2019-07-30 Kaiser Optical Systems, Inc. Real-time characterization of pharmaceutical tablet coatings using Raman spectroscopy
DE102016222667A1 (de) * 2016-11-17 2018-05-17 Robert Bosch Gmbh Verfahren zum Betrieb einer Anlage zum Herstellen von pharmazeutischen Produkten
US10323932B1 (en) 2017-12-28 2019-06-18 Ford Motor Company System for inspecting vehicle bodies
JP7263047B2 (ja) 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
CN110411978B (zh) * 2019-07-26 2020-05-22 中国农业大学 一种物料均匀性检测设备及检测方法
JP7312676B2 (ja) 2019-11-13 2023-07-21 ナブテスコ株式会社 ブレーキ異常判定装置、ブレーキ状態記憶装置、異常判定方法、異常判定プログラム、及びブレーキ制御装置
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4426019A (en) 1981-10-15 1984-01-17 The Coca-Cola Company Membrane seal and knife combination for a post-mix beverage dispensing system
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
DE59000232D1 (de) 1989-02-11 1992-09-10 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
KR100222252B1 (ko) 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
US5656650A (en) 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
CA2456034A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
WO2003080057A1 (fr) 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Comprime-noyau de taille reduite contenant de la nifedipine
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
CA2536111A1 (en) 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005079751A2 (en) 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100978592B1 (ko) 2005-05-10 2010-08-27 테바 파마슈티컬 인더스트리즈 리미티드 안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
WO2008003560A1 (en) 2006-07-03 2008-01-10 Novo Nordisk A/S Coupling for injection devices
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
EP2099431B1 (en) 2006-11-28 2013-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
WO2009054550A1 (en) 2007-10-25 2009-04-30 Bayer Yakuhin, Ltd. Nifedipine-containing press coated tablet and method of preparing the same
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
WO2012031124A2 (en) 2010-09-03 2012-03-08 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants

Also Published As

Publication number Publication date
IN2014DN09045A (es) 2015-05-22
HK1204292A1 (en) 2015-11-13
PH12014502469A1 (en) 2014-12-22
JP6231553B2 (ja) 2017-11-15
CO7190241A2 (es) 2015-02-19
MX2014013320A (es) 2015-08-10
CN104507459A (zh) 2015-04-08
AR090940A1 (es) 2014-12-17
TW201410266A (zh) 2014-03-16
PE20142284A1 (es) 2014-12-17
KR20150007297A (ko) 2015-01-20
BR112014027618A2 (pt) 2017-06-27
US20130309302A1 (en) 2013-11-21
EP2846777B1 (en) 2016-10-26
IL235040A0 (en) 2014-12-31
CA2872542A1 (en) 2013-11-14
EA201492026A1 (ru) 2015-09-30
CL2014002988A1 (es) 2015-03-13
ES2612532T3 (es) 2017-05-17
WO2013167453A1 (en) 2013-11-14
US9539176B2 (en) 2017-01-10
ECSP14025965A (es) 2015-12-31
EP2846777A1 (en) 2015-03-18
JP2015515999A (ja) 2015-06-04
CR20140511A (es) 2014-12-02
SG11201406363VA (en) 2014-11-27
UY34786A (es) 2013-11-29
AU2013258273A1 (en) 2014-11-13
GT201400245A (es) 2015-08-25

Similar Documents

Publication Publication Date Title
CR20140511A (es) Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo
UY32260A (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CR20130008A (es) Anillos condensados de pirimidinas y triazinas y su uso para el tratamiento y/o profilaxis de enfermedades cardiovasculares
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
CO6940408A2 (es) Composiciones en forma de comprimido de disolución rápida para administración vaginal
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
BR112012028788A2 (pt) fabricação de grânulos sem ativos
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
IL239670B (en) Monolithic administration form for delayed release of a combination of active substances
CU20140126A7 (es) Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo
BR112014032037A2 (pt) formulações para a preparação de comprimidos de liberação imediata para uso oral contendo uma baixa dosagem de mifepristona para o tratamento de endometriose, comprimidos desse modo obtidos e seu processo de preparação
EP2799043A4 (en) VAGINAL RING WITH MELOXICAM AND A MEANS FOR MODULATING THE RELEASE OF AN ACTIVE AGGREGATE FOR USE AS A CONTINUOUS RECIPIENT OF PREVENTION IN WOMEN
PE20170201A1 (es) Formas de dosificacion farmaceutica
BR112018013121A2 (pt) formulação de combinação farmacêutica
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos